Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	Children with migraine	Adverse effects with topiramate with placebo Absolute results not reported	RR 1.53 95% CI 1.05 to 2.24 P value not reported	Small effect size	topiramate
Systematic review	Children with migraine	Anorexia with topiramate with placebo Absolute results not reported	RR 1.93 95% CI 0.76 to 4.92 P value not reported		Not significant
Systematic review	Children with migraine	Insomnia with topiramate with placebo Absolute results not reported	RR 1.89 95% CI 0.22 to 16.22 P value not reported		Not significant
Systematic review	Children with migraine	Fatigue with topiramate with placebo Absolute results not reported	RR 0.69 95% CI 0.29 to 1.62 P value not reported		Not significant
Systematic review	Children with migraine	Dizziness with topiramate with placebo Absolute results not reported	RR 5.30 95% CI 0.30 to 92.50 P value not reported		Not significant
RCT	44 children with migraine In review	Proportion of participants who lost weight 17/21 (81%) with topiramate 3/21 (14%) with placebo	Significance not assessed
RCT	44 children with migraine In review	Proportion of participants with lack of concentration in school 4/21 (19%) with topiramate 0/21 (0%) with placebo	Significance not assessed
RCT	44 children with migraine In review	Proportion with paraesthesias 5/21 (24%) with topiramate 0/21 (0%) with placebo	Significance not assessed
RCT 3-armed trial	106 participants aged 12–17 years with at least a 6-month history of migraine In review	Proportion of participants who lost weight (<10% from baseline) during 16-week treatment period 28% with topiramate 50 mg daily 48% with topiramate 100 mg daily 22% with placebo Absolute numbers not reported	Significance not assessed
RCT 3-armed trial	106 participants aged 12–17 years with at least a 6-month history of migraine Further report of reference	Mean change in reaction time (in milliseconds) end of a 16-week treatment period +33.7 with topiramate 100 mg daily –3.5 with placebo	P = 0.028	Effect size not calculated	placebo
RCT 3-armed trial	106 participants aged 12–17 years with at least a 6-month history of migraine Further report of reference	Pattern recognition memory: change in mean correct latency (in milliseconds) end of a 16-week treatment period +51.3 with topiramate 100 mg daily –132.7 with placebo	P = 0.027	Effect size not calculated	placebo
RCT 3-armed trial	106 participants aged 12–17 years with at least a 6-month history of migraine Further report of reference	Change in rapid visual information processing mean latency (in milliseconds) end of a 16-week treatment period +23.0 with topiramate 100 mg daily –87.9 with placebo	P = 0.04	Effect size not calculated	placebo